Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terbinafine gel - MediQuest Therapeutics

X
Drug Profile

Terbinafine gel - MediQuest Therapeutics

Alternative Names: IVR-101; MQX-5866; MQX-5867; Organogel - MediQuest Therapeutics; Organogel of terbinafine 2% or 6%

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediQuest Therapeutics
  • Developer Ivrea Pharmaceuticals
  • Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Onychomycosis

Most Recent Events

  • 09 Feb 2016 No development reported - Phase-II for Onychomycosis in USA (Topical)
  • 28 Aug 2012 Clinical development is ongoing in USA
  • 28 Aug 2012 Onychomycosis therapies (topical gels) - MediQuest is available for licensing as of 28 Aug 2012. http://www.mqti.com

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top